SBIR/STTR Research Award

Discovery of Antagonists of Phosphoinositide Signaling

Award identifier 991cd893708454a2e9cdfb453ed8cb1023b5bb9e79c3a9f02a17bfe423f796d9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$500,000

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ECHELON BIOSCIENCES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
EDK8FFD24SC4
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Phosphoinositides are key lipid second messengers in many cellular signaling processes. In particular, the activity of phosphatidylinositol 3-kinase (PI 3-K), and the synthesis of its lipid products, is important in pathways mediating cell proliferation, survival, and motility. Alterations in PI 3-K mediated signaling are common to many cancers. Targeting PI 3-K activity is recognized as a potential anti-cancer strategy. The lipid products of PI 3-K act as second messengers by activating downstream protein effectors by their recruitment to specific domains in the plasma membrane. We propose a new strategy for inhibiting PI 3-K mediated signaling in disease by preventing the interaction of PI(3,4,5)P3 with these protein effectors. In vitro and cell-based assays will be developed to determine the interaction of selected effectors with PI(3,4,5)P3. These will be used to identify compounds which block the interaction of PI(3,4,5)P3 with effector proteins using libraries of synthetic small molecules and of compounds from natural sources. The mode of action of inhibitors will also be explored in cell culture. Identification and characterization of novel antagonists of PI 3-K signaling may lead to new therapies for cancer, inflammation, and diabetes.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

40 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $11,763,634. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.